letrozole has been researched along with Bone Loss, Osteoclastic in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 9.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 5.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| "Several adjuvant trials evaluating aromatase inhibitors in postmenopausal women with early breast cancer have shown significant improvement upon, or extension of the efficacy benefits of, standard therapy with tamoxifen, and treatments were generally well tolerated." | 4.82 | Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit. ( Henderson, IC, 2004) |
| "All three AIs induced increases in bone resorption markers, but no significant differences were observed in their effects on bone turnover markers." | 2.73 | Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. ( Clack, G; Eastell, R; Finkelman, RD; Fraser, WD; Hannon, RA; Lakner, G; McCloskey, EV; Miyamoto, A, 2007) |
| "Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0." | 2.70 | Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. ( Heshmati, HM; Khosla, S; Melton, LJ; O'Fallon, WM; Riggs, BL; Robins, SP, 2002) |
| "Letrozole is a reversible nonsteroidal aromatase inhibitor that is widely used in postmenopausal breast cancer patients." | 1.56 | Letrozole Suppresses the Fusion of Osteoclast Precursors through Inhibition of p38-Mediated DC-STAMP Pathway. ( Choi, Y; Heo, SC; Kim, HJ; Kim, YD; Seong, HS, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, HJ | 1 |
| Seong, HS | 1 |
| Choi, Y | 1 |
| Heo, SC | 1 |
| Kim, YD | 1 |
| Kalam, A | 1 |
| Talegaonkar, S | 1 |
| Vohora, D | 1 |
| Mohamed, I | 1 |
| Yeh, JK | 1 |
| McCaig, FM | 1 |
| Renshaw, L | 1 |
| Williams, L | 1 |
| Young, O | 1 |
| Murray, J | 1 |
| Macaskill, EJ | 1 |
| McHugh, M | 1 |
| Hannon, R | 1 |
| Dixon, JM | 1 |
| Eidtmann, H | 1 |
| de Boer, R | 1 |
| Bundred, N | 1 |
| Llombart-Cussac, A | 1 |
| Davidson, N | 1 |
| Neven, P | 1 |
| von Minckwitz, G | 1 |
| Miller, J | 1 |
| Schenk, N | 1 |
| Coleman, R | 1 |
| Henderson, IC | 1 |
| Harvey, HA | 1 |
| Goss, PE | 1 |
| Hadji, P | 1 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Thomsen, T | 1 |
| Banke-Bochita, J | 1 |
| McCloskey, EV | 1 |
| Hannon, RA | 1 |
| Lakner, G | 1 |
| Fraser, WD | 1 |
| Clack, G | 1 |
| Miyamoto, A | 1 |
| Finkelman, RD | 1 |
| Eastell, R | 1 |
| Heshmati, HM | 1 |
| Khosla, S | 1 |
| Robins, SP | 1 |
| O'Fallon, WM | 1 |
| Melton, LJ | 1 |
| Riggs, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for letrozole and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuva | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clin | 2004 |
5 trials available for letrozole and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; | 2010 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; B | 2010 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
Topics: Adrenal Glands; Alkaline Phosphatase; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; | 2007 |
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.
Topics: Aged; Aromatase Inhibitors; Bone Remodeling; Bone Resorption; Double-Blind Method; Enzyme Inhibitors | 2002 |
3 other studies available for letrozole and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Letrozole Suppresses the Fusion of Osteoclast Precursors through Inhibition of p38-Mediated DC-STAMP Pathway.
Topics: Animals; Bone Resorption; Cell Differentiation; Cell Fusion; Cell Proliferation; Dendritic Cells; Do | 2020 |
Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers; Bone Remodeling; Bone Resorption; Cyclohe | 2017 |
Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats.
Topics: Animals; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Development; Bon | 2009 |